Eli Lilly Zepbound Performance - Search News

Order byBest matchMost fresh

News

Zepbound beats Wegovy for weight loss

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the

Continue reading

EconoTimes · 3d

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

· 13d · on MSN

Zepbound Miss Hits Eli Lilly Shares: What’s Behind the Slump?

19h

1LLY : Unpacking the Latest Options Trading Trends in Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

13d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

22h

Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

13don MSN

Eli Lilly’s Shares Sink on Investor Concerns About CVS Move

Eli Lilly & Co.’s shares dropped in morning trading after CVS Health Corp. announced a plan to drop its blockbuster ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results